Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics
暂无分享,去创建一个
Kalet León | Karina García-Martínez | Tania Carmenate | K. Leon | T. Carmenate | Karina García-Martínez
[1] D. Lauffenburger,et al. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. , 2005, Biochemistry.
[2] J. Sprent,et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25 , 2010, Proceedings of the National Academy of Sciences.
[3] J. Kahn,et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.
[4] D. Klatzmann,et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. , 2010, The Journal of clinical investigation.
[5] Vijay S. Pande,et al. Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.
[6] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[7] J. Shimizu,et al. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. , 2000, International immunology.
[8] J. Sprent,et al. Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.
[9] A. Church. Clinical advances in therapies targeting the interleukin-2 receptor. , 2003, QJM : monthly journal of the Association of Physicians.
[10] J. Carneiro,et al. Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. , 2000, Journal of theoretical biology.
[11] A. Freitas,et al. Homeostasis of Peripheral CD4+ T Cells: IL-2Rα and IL-2 Shape a Population of Regulatory Cells That Controls CD4+ T Cell Numbers1 , 2002, The Journal of Immunology.
[12] S. Zheng,et al. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.
[13] K. Leon,et al. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. , 2013, Immunobiology.
[14] K. Leon,et al. Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. , 2012, International immunology.
[15] A. Tyznik,et al. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.
[16] Shimon Sakaguchi,et al. Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.
[17] E. Wherry,et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.
[18] T. Malek,et al. Normal Lymphoid Homeostasis and Lack of Lethal Autoimmunity in Mice Containing Mature T Cells with Severely Impaired IL-2 Receptors1 , 2000, The Journal of Immunology.
[19] Ethan M. Shevach,et al. CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.
[20] A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus. , 2007, Vaccine.
[21] C. Hallahan,et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.
[22] G. Pantaleo,et al. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. , 2009, The Journal of allergy and clinical immunology.
[23] Kendall A. Smith,et al. Interleukin-2: inception, impact, and implications. , 1988, Science.
[24] K. Leon,et al. Modeling the role of IL-2 in the interplay between CD4+ helper and regulatory T cells: assessing general dynamical properties. , 2010, Journal of theoretical biology.
[25] J. Pow-Sang,et al. Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma , 2008, Journal of immunotherapy.
[26] J. Metcalf,et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.
[27] T. Hünig,et al. Control of T cell hyperactivation in IL‐2‐deficient mice by CD4+CD25– and CD4+CD25+ T cells: evidence for two distinct regulatory mechanisms , 2001, European journal of immunology.
[28] Ana R. Pacios,et al. Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.
[29] E. Montero,et al. Interleukin‐2 Mastering Regulation in Cancer and Autoimmunity , 2007, Annals of the New York Academy of Sciences.
[30] J. Sprent,et al. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease , 2006, Expert opinion on biological therapy.
[31] J. Metcalf,et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.
[32] C. van den Dool,et al. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.
[33] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[34] T. Hünig,et al. evidence for two distinct regulatory mechanisms , 2001 .
[35] R. Lempicki,et al. Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Schlom,et al. IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells1 , 2008, The Journal of Immunology.
[37] M. Veldhoen,et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. , 2005, International immunology.
[38] Antonio A. Freitas,et al. Indexation as a Novel Mechanism of Lymphocyte Homeostasis: The Number of CD4+CD25+ Regulatory T Cells Is Indexed to the Number of IL-2-Producing Cells1 , 2006, The Journal of Immunology.
[39] J. Bluestone,et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.
[40] Y. Soong,et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. , 2007, Immunology letters.
[41] J. Schlom,et al. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity , 2007, Cancer Immunology, Immunotherapy.
[42] Kendall A. Smith,et al. The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs , 2006, Medical immunology.
[43] T. Hirano,et al. IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb1 , 2006, The Journal of Immunology.
[44] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[45] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Bluestone,et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.
[47] J. Metcalf,et al. In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients , 2005 .
[48] S. Morrison,et al. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. , 1996, Journal of immunology.
[49] M. Bevan,et al. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2–anti–IL-2 complex treatment in vivo , 2007, The Journal of experimental medicine.
[50] G. Pantaleo,et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells , 2010, Proceedings of the National Academy of Sciences.
[51] Kendall A. Smith,et al. The quantal theory of how the immune system discriminates between "self and non-self" , 2004, Medical immunology.